skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

32 Total results for product and free and sample content found

Pink Sheet

Trumps Drug Pricing Plan: The Headlines Are The Goal - But Also A Threat

By Michael McCaughan 16 Jun 2022

US Election Drug Pricing Reform

The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.

Topic US Election 2020

US Election 2020: Almost All House Members Backed By Industry PAC Dollars Retain Seats

By Sue Darcey 16 Jun 2022

Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.

Topic US Election 2020 Policy & Regulation Legislation

China-US Relationship Hinges On Changing Internal, External Forces

16 Jun 2022

US Election China Relations

Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.

Topic US Election 2020 China

Pink Sheet – US Election and New Administration Coverage

26 Jan 2021

Stay informed of the latest news from the recent US election and understand how the shift in power will affect pharma regulatory and policy issues both within the United States and abroad. Pink Sheet takes you behind the US election headlines for analysis on the real impact you can expect to see on your business.

Topic us-election-2020

With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says

08 Dec 2020

Covid19 Biden Transition

As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.

Topic Coronavirus vaccines us-election-2020

10 Predictions On How Health Policy Could Change Under A Biden Presidency

29 Nov 2020

Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.

Topic us-election-2020 Leadership policy-and-regulation

US Drug Pricing Reform Post-Election: Scenarios To Consider And Lessons Learned

18 Nov 2020

US Election Drug Pricing Reform

Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.

Topic us-election-2020 policy-and-regulation drug-pricing

US Election 2020: Industry Loses Three Favored Incumbents In Battle For Senate Control

18 Nov 2020

US Election senate battle

A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election

Topic us-election-2020 Legislation

Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly

18 Nov 2020

Biden Administration Rx Pricing

A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry

Topic us-election-2020 drug-pricing

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: